AFRIN NO DRIP SEVERE CONGESTION OTC
Generic Name and Formulations:
Oxymetazoline HCl 0.05%; pump mist; contains menthol.
Merck & Co., Inc.
Indications for AFRIN NO DRIP SEVERE CONGESTION:
Adults and Children:
<6yrs: individualize. ≥6yrs: 2–3 sprays in each nostril not more than every 10–12 hours. Max 2 doses/day.
Use >3 days; may worsen nasal congestion.
Heart disease. Hypertension. Thyroid disease. Diabetes. Urinary retention. Enlarged prostate. Pregnancy. Nursing mothers.
Local effects (eg, burning, stinging, sneezing, increased nasal discharge).
Original nasal spray—30mL; No Drip Original, Severe Congestion, Extra Moisturizing, Sinus—15mL
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies